FDA Clears First Continuous Glucose-Ketone Monitor: Abbott’s Libre Duo 10 Day Transforms Diabetes Care

August 30, 2026

Pharmacy Times USA

Overview

The FDA has authorized Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged 2 and older with diabetes. This marks the first continuous ketone monitoring wearable in the U.S. and the first globally to continuously track both glucose and ketones in a single system. The approval signifies a critical advance in preventing diabetic ketoacidosis (DKA).

In Depth

Key Findings

Pharmacy Times reported on August 27, 2026, that the U.S. Food and Drug Administration (FDA) has authorized Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged 2 years and older. This landmark approval positions Libre Duo 10 Day as the first wearable device in the U.S. capable of continuous ketone monitoring and, more broadly, the world’s first single system to continuously track both glucose and ketone levels.

Technical and Clinical Details

The Libre Duo 10 Day system operates via a small, patch-type sensor worn on the patient’s arm, providing real-time measurements of both glucose and beta-hydroxybutyrate (BHB), a primary ketone body. The device is designed for continuous wear for up to 10 days, during which it collects minute-by-minute data and transmits it to a compatible smartphone application. A crucial feature is its ability to automatically issue alerts when ketone levels rise, enabling patients and caregivers to detect abnormalities before the onset of diabetic ketoacidosis (DKA) and take swift action. Clinical data suggest that early detection of rising ketones can reduce DKA-related hospitalization risk by up to 70%, making it a vital tool for safer diabetes management, especially for pediatric patients and those using insulin pumps.

Background and Industry Context

Historically, ketone measurement for diabetes patients typically involved inconvenient finger-prick blood tests or urine strip tests. These methods were cumbersome and unsuitable for real-time trend monitoring. Diabetic ketoacidosis (DKA) is an acute complication caused by an abnormal accumulation of ketones in the body due to insulin deficiency, leading to severe acidosis. DKA is particularly challenging in pediatric Type 1 diabetes, where it often presents as the initial diagnosis. Abbott’s Libre Duo 10 Day offers a revolutionary solution to this long-standing problem through its convenient and continuous monitoring, significantly reducing patient burden and improving quality of life. This integrated approach also aligns with global trends towards more proactive and patient-centric healthcare.

Strategic Significance and Outlook

Pharmacy Times emphasizes the importance of pharmacists being equipped to counsel patients effectively on this new technology. This device has the potential to redefine the standard of diabetes care, fostering an environment where patients can live with greater confidence and reduced anxiety about acute complications. Furthermore, it reinforces Abbott’s leadership in the continuous glucose monitoring market and is expected to spur other medical device manufacturers to accelerate the development of similar dual-sensor technologies. In the long term, such multifunctional biosensors could be applied to a broader range of disease monitoring, contributing to the further advancement of preventive medicine globally.

Source: https://www.pharmacytimes.com/view/fda-clears-first-continuous-glucose-ketone-monitor

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.